Phase II study of axitinib intensification compared to nivolumab alone after induction with ipilimumab plus nivolumab in patients with mRCC without previous complete response (AxIn study).

被引：0

作者：

Ciccarese, Chiara

Verzoni, Elena

Bimbatti, Davide

Buti, Sebastiano

Calabro, Fabio

Galli, Luca

Scagliarini, Sarah

Fornarini, Giuseppe

Baldessari, Cinzia

Bilancia, Domenico

Facchini, Gaetano

Cattrini, Carlo

Masini, Cristina

Giganti, Maria Olga

Scandurra, Giuseppa

Nole, Franco

Berruti, Alfredo

Milella, Michele

Antonuzzo, Lorenzo

Iacovelli, Roberto

机构：

[1] Univ Cattolica Sacro Cuore, Fdn Policlin Univ A Gemelli IRCCS, Oncol Unit, Rome, Italy

[2] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy

[3] IOV IRCCS, Ist Oncol Veneto, Oncol Unit 1, Padua, Italy

[4] Univ Hosp Parma, Fontevivo, Italy

[5] IFO Ist Regina Elena, Rome, Italy

[6] Univ Pisana, UO Oncol Med 2 Univ Azienda Osped, Pisa, Italy

[7] Cardarelli Hosp, Dept Oncol, Naples, Italy

[8] IRCCS Osped Policlin San Martino, Genoa, Italy

[9] Azienda Osped Univ Policlin Modena, Oncol Unit, Modena, Italy

[10] Azienda Osped S Carlo, Potenza, Italy

[11] SM delle Grazie Hosp, Med Oncol Unit, Pozzuoli, Italy

[12] Azienda Osped Maggiore Carita, Novara, Italy

[13] AUSL IRCCS Reggio Emilia, Reggio Emilia, Italy

[14] Osped Cremona, Cremona, Italy

[15] Humanitas Ctr Catanese Oncol, Catania, Italy

[16] IRCCS Ist Europeo Oncol, Milan, Italy

[17] Univ Brescia, Dept Med & Surg Special Radiol Sci & Publ Hlth, Med Oncol Unit, ASST Spedali Civili, Brescia, Italy

[18] Univ Verona, Sch Med, Sect Oncol, Verona, Italy

[19] Verona Univ Hosp Trust, Verona, Italy

[20] Sodc Ematol Azienda Osped Careggi, Florence, Italy

[21] Fdn Policlin Univ A Gemelli, IRCCS, Rome, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期

关键词：

283-2494-9200; 261-492-3532-2370-7650-2700; 261-492-11294; 261-492-3532-2370; 261-492-3532-2373; 261-492-5651-9270-5652; 261-492-5651-9270-5657; 4; 3; 2; 14; 319; 3581; 137; 3585; 8; 1;

D O I：

10.1200/JCO.2024.42.4_suppl.TPS494

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：TPS494 / TPS494

页数：1

共 50 条

[31] A phase 2 study of nivolumab (NIVO) alone or plus ipilimumab (IPI) for patients with locally advanced unresectable (IaBCC) or metastatic basal cell carcinoma (mBCC).
Stein, Julie E.
Brothers, Patricia
Applebaum, Katie
Gaskin, Angela
Wang, Hao
Taube, Janis M.
Lipson, Evan J.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[32] Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study
Long, Georgina, V
Atkinson, Victoria
Lo, Serigne N.
Guminski, Alexander
Sandhu, Shahneen K.
Brown, Michael P.
Gonzalez, Maria
Mcarthur, Grant A.
Menzies, Alexander M.
LANCET ONCOLOGY, 2025, 26 (03): : 320 - 330
[33] FOLFOX plus nivolumab and ipilimumab versus FOLFOX induction followed by nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Results from the randomized phase II Moonlight trial of the AIO
Lorenzen, S.
Thuss-Patience, P. C.
Folprecht, G.
Knorrenschild, J. Riera
Heinemann, V.
Goekkurt, E.
Dechow, T. N.
Ettrich, T. J.
Luley, K. B.
Moulin, J. C.
Lindig, U.
Angermeier, S.
Waidmann, O.
Pink, D.
Bolling, C.
Junge, S.
Pauligk, C.
Gaiser, T.
Goetze, T. O.
Al-Batran, S. E.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1099 - S1099
[34] Phase I/II study of ipilimumab plus nivolumab combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma.
Jain, Rohit K.
Yang, Yuanquan
Chadha, Juskaran
Chatwal, Monica Sheila
Kish, Julie Ann
Raymond, Sarah
Rembisz, Jennifer
Jameel, Ghazal
Mustasam, Arfa
Poehlman, Trey
Fan, Wenyi
Kim, Youngchul
Dhillon, Jasreman
Alemany, Carlos A.
Mortazavi, Amir
Zhang, Jingsong
Sonpavde, Guru P.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[35] A phase II study of nivolumab with ipilimumab and cabozantinib in patients with untreated renal cell carcinoma brain metastases.
Wang, Jianbo
Campbell, Matthew T.
Shah, Amishi Yogesh
Goswami, Sangeeta
Msaouel, Pavlos
Alhalabi, Omar
Hahn, Andrew Warren
Kovitz, Craig A.
Jana, Bagi Rp
Araujo, John C.
Gao, Jianjun
Zurita, Amado J.
Jonasch, Eric
Corn, Paul Gettys
Tannir, Nizar M.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[36] Phase Ib study of Intraperitoneal (IP) administration of nivolumab plus ipilimumab in patients with recurrent gynaecologic malignancies with peritoneal involvement
Hinchcliff, E.
Mosely, A.
Hull, S.
Westin, S.
Sood, A.
Schmeler, K.
Taylor, J.
Huang, S.
Sheth, R.
Lu, K.
Jazaeri, A.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S806 - S807
[37] A Phase II Trial of Nivolumab With Chemotherapy Followed by Maintenance Nivolumab in Patients With Pleural Mesothelioma After Surgery: The NICITA Study Protocol
Shah, Rajiv
Klotz, Laura, V
Chung, Inn
Feisst, Manuel
Schneider, Marc A.
Riedel, Johanna
Bischoff, Helge
Eichhorn, Martin E.
Thomas, Michael
CLINICAL LUNG CANCER, 2020, 22 (02) : 142 - 146
[38] Phase 1 study to evaluate safety and efficacy of ipilimumab plus nivolumab plus external beam radiotherapy in patients with metastatic melanoma.
Postow, Michael Andrew
Knox, Susan Jane
McCabe, Danielle
Macri, Mary J.
Schwarzenberger, Paul
Ricciardi, Toni
Ryan, Aileen
Venhaus, Ralph Rudolph
Barker, Christopher Andrew
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[39] Nimbus: A phase II study of nivolumab plus ipilimumab in metastatic hypermutated HER2-negative breast cancer.
Barroso-Sousa, Romualdo
Trippa, Lorenzo
Lange, Paulina
Andrews, Chelsea
McArthur, Heather L.
Haley, Barbara B.
Rugo, Hope S.
Emens, Leisha A.
Winer, Eric P.
Mittendorf, Elizabeth A.
Tolaney, Sara M.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[40] Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE)
McKay, Rana R.
McGregor, Bradley A.
Xie, Wanling
Braun, David A.
Wei, Xiao
Kyriakopoulos, Christos E.
Zakharia, Yousef
Maughan, Benjamin L.
Rose, Tracy L.
Stadler, Walter M.
McDermott, David F.
Harshman, Lauren C.
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (36) : 4240 - +

← 1 2 3 4 5 →